NASDAQ:SERA

Sera Prognostics (SERA) Stock Forecast, Price & News

$3.25

+0.03 (+0.93%)

(As of 09:30 AM ET)

Compare

Today's Range: $3.25
▼
$3.25
50-Day Range: $3.20
▼
$3.90
52-Week Range: $1.10
▼
$4.25

Volume: 313 shs
Average Volume: 813,035 shs
Market Capitalization: $100.91 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $6.25

Sera Prognostics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.67 Rating Score
Upside/Downside: 92.3% Upside
$6.25 Price Target
Short Interest: Healthy
1.07% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.38) to ($1.32) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

973rd out of 980 stocks

Medical Laboratories Industry

22nd out of 22 stocks

3.3

Analyst's Opinion

Consensus Rating
Sera Prognostics has received a consensus rating of Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.25, Sera Prognostics has a forecasted upside of 92.3% from its current price of $3.25.
Amount of Analyst Coverage
Sera Prognostics has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.07% of the float of Sera Prognostics has been sold short.
Short Interest Ratio / Days to Cover
Sera Prognostics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Sera Prognostics has recently decreased by 2.46%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Sera Prognostics does not currently pay a dividend.
Dividend Growth
Sera Prognostics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SERA.

N/A

News and Social Media Coverage

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Sera Prognostics insiders have not sold or bought any company stock.
Percentage Held by Insiders
15.60% of the stock of Sera Prognostics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 31.32% of the stock of Sera Prognostics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Sera Prognostics are expected to grow in the coming year, from ($1.38) to ($1.32) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Sera Prognostics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Sera Prognostics is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Sera Prognostics has a P/B Ratio of 1.02. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Sera Prognostics (NASDAQ:SERA) Stock

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Receive SERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Sera Prognostics and its competitors with MarketBeat's FREE daily newsletter.

SERA Stock News Headlines

May 25, 2023 | marketwatch.com

Sera Prognostics Reduces Headcount to Cut Costs in Optimization Strategy

May 25, 2023 | finance.yahoo.com

Sera Prognostics Announces Commercial Changes and Actions to Optimize Business for Market Success Toward Accelerating Test Adoption and Revenue

June 5, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 17, 2023 | americanbankingnews.com

Equities Analysts Offer Predictions for Sera Prognostics, Inc.'s Q2 2023 Earnings (NASDAQ:SERA)

May 15, 2023 | msn.com

Sera Prognostics CEO Critchfield to step down in June

May 15, 2023 | finance.yahoo.com

Sera Prognostics Announces Retirement of President and CEO Dr. Greg Critchfield and Appointment of Board Member Zhenya Lindgardt as Interim CEO

May 11, 2023 | finanznachrichten.de

Sera Prognostics, Inc.: Sera Prognostics Reports First Quarter 2023 Financial Results

May 10, 2023 | msn.com

Recap: Sera Prognostics Q1 Earnings

June 5, 2023 | Edge On The Street (Ad)

AI is Unstoppable. Now Is The Time!

AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.

May 10, 2023 | finance.yahoo.com

SERA PROGNOSTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS

May 10, 2023 | finance.yahoo.com

Sera Prognostics, Inc. (SERA) Reports Q1 Loss

May 10, 2023 | marketwatch.com

Premature Rupture of Membranes (PROM) Testing Market Report | Research Across The World 2031

May 3, 2023 | benzinga.com

Sera Prognostics Stock (NASDAQ:SERA), Dividends

April 27, 2023 | finance.yahoo.com

Sera Prognostics Announces Conference Call and Webcast of First Quarter Fiscal Year 2023 Financial Results on May 10, 2023

April 27, 2023 | americanbankingnews.com

Sera Prognostics, Inc. (NASDAQ:SERA) Short Interest Down 24.9% in April

April 24, 2023 | finance.yahoo.com

Sera Prognostics, Inc. (SERA) Loses -13.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 29, 2023 | americanbankingnews.com

Sera Prognostics, Inc. (NASDAQ:SERA) Expected to Earn Q1 2023 Earnings of ($0.37) Per Share

March 28, 2023 | americanbankingnews.com

Q1 2023 EPS Estimates for Sera Prognostics, Inc. Raised by Analyst (NASDAQ:SERA)

March 27, 2023 | finance.yahoo.com

All You Need to Know About Sera Prognostics, Inc. (SERA) Rating Upgrade to Buy

March 27, 2023 | marketwatch.com

Latest Premature Rupture of Membranes (PROM) Testing Market Growth Outlook 2023-2030 | New Report Highlights

March 27, 2023 | insidermonkey.com

Sera Prognostics, Inc. (NASDAQ:SERA) Q4 2022 Earnings Call Transcript

March 24, 2023 | finance.yahoo.com

Sera Prognostics Full Year 2022 Earnings: Revenues Miss Expectations

March 24, 2023 | americanbankingnews.com

Q1 2024 Earnings Forecast for Sera Prognostics, Inc. Issued By William Blair (NASDAQ:SERA)

March 22, 2023 | finance.yahoo.com

Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates

March 22, 2023 | finance.yahoo.com

SERA PROGNOSTICS REPORTS FOURTH QUARTER 2022 FINANCIAL RESULTS

March 21, 2023 | markets.businessinsider.com

Sera Prognostics A earnings preview: what Wall Street is expecting

March 21, 2023 | americanbankingnews.com

Sera Prognostics (SERA) to Release Quarterly Earnings on Wednesday

See More Headlines

SERA Price History

30 days | 90 days | 365 days | Advanced Chart

SERA Company Calendar

Last Earnings: 3/22/2023
Today: 6/05/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical laboratories
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SERA
CUSIP: N/A
CIK: 1534969
Web: www.seraprognostics.com
Phone: 801-990-0520
Fax: N/A
Employees: 113
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $6.25
High Stock Price Forecast: $11.00
Low Stock Price Forecast: $1.50
Forecasted Upside/Downside: +92.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.67
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.37)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-44,190,000.00
Net Margins: -12,891.82%
Pretax Margin: -12,891.82%
Return on Equity: -41.18%
Return on Assets: -36.71%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 5.23
Quick Ratio: 5.23

Sales & Book Value

Annual Sales: $270,000.00
Price / Sales: 373.75
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.91 per share
Price / Book: 1.12

Miscellaneous

Outstanding Shares: 31,050,000
Free Float: 26,208,000
Market Cap: $100.91 million
Optionable: Not Optionable
Beta: 0.26

Key Executives

Dr. Gregory C. Critchfield M.D. (Age 70)
M.S., Exec. Chairman, CEO & Pres
Comp: $775.1k

Mr. Robert G. Harrison (Age 57)
Chief Information Officer
Comp: $384.18k

Mr. Benjamin G. Jackson J.D. (Age 43)
Gen. Counsel
Comp: $410.75k

Dr. Steven W. Graves
Co-Founder and Co-Chairman of The Scientific Advisory Board

Dr. M. Sean Esplin M.D.
Co-Founder and Co-Chairman of Scientific Advisory Board

Mr. Jay M. Moyes M.B.A. (Age 69)
MBA, Chief Financial Officer

Dr. John J. Boniface Ph.D. (Age 60)
Chief Scientific Officer

Ms. Nadia F. Altomare (Age 52)
Chief Commercial Officer

Dr. Paul Kearney Ph.D. (Age 55)
Chief Data Officer

Dr. Michael R. Foley M.D.
Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SERA Stock - Frequently Asked Questions

Should I buy or sell Sera Prognostics stock right now?: 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sera Prognostics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SERA shares.
View SERA analyst ratings or view top-rated stocks.
What is Sera Prognostics' stock price forecast for 2023?: 3 Wall Street analysts have issued twelve-month price objectives for Sera Prognostics' stock. Their SERA share price forecasts range from $1.50 to $11.00. On average, they predict the company's stock price to reach $6.25 in the next year. This suggests a possible upside of 92.3% from the stock's current price.
View analysts price targets for SERA or view top-rated stocks among Wall Street analysts.
How have SERA shares performed in 2023?: Sera Prognostics' stock was trading at $1.26 at the beginning of the year. Since then, SERA shares have increased by 157.9% and is now trading at $3.25.
View the best growth stocks for 2023 here.
When is Sera Prognostics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our SERA earnings forecast.
How were Sera Prognostics' earnings last quarter?: Sera Prognostics, Inc. (NASDAQ:SERA) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. The firm had revenue of $0.07 million for the quarter, compared to the consensus estimate of $0.13 million. Sera Prognostics had a negative trailing twelve-month return on equity of 41.18% and a negative net margin of 12,891.82%.
When did Sera Prognostics IPO?: (SERA) raised $75 million in an initial public offering on Thursday, July 15th 2021. The company issued 4,687,500 shares at $15.00-$17.00 per share.

What is Sera Prognostics' stock symbol?: Sera Prognostics trades on the NASDAQ under the ticker symbol "SERA."
Who are Sera Prognostics' major shareholders?: Sera Prognostics' stock is owned by many different retail and institutional investors. Top institutional investors include Baker BROS. Advisors LP (5.77%), Sanders Morris Harris LLC (1.41%), Geode Capital Management LLC (0.47%), Riverview Capital Advisers LLC (0.33%), Requisite Capital Management LLC (0.18%) and State Street Corp (0.16%). Insiders that own company stock include Benjamin Jackson and John J Boniface.
View institutional ownership trends.
How do I buy shares of Sera Prognostics?: Shares of SERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Sera Prognostics' stock price today?: One share of SERA stock can currently be purchased for approximately $3.25.
How much money does Sera Prognostics make?: Sera Prognostics (NASDAQ:SERA) has a market capitalization of $100.91 million and generates $270,000.00 in revenue each year. The company earns $-44,190,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.
How many employees does Sera Prognostics have?: The company employs 113 workers across the globe.
How can I contact Sera Prognostics?: The official website for the company is www.seraprognostics.com. The company can be reached via phone at 801-990-0520 or via email at peter@capcommpartners.com.

This page (NASDAQ:SERA) was last updated on 6/5/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial